GhassanEEl-HaddadMD
Interventional Radiology • Tampa, FLSenior Member, Interventional Radiology, Section Head of Radionuclide Therapy Program, Moffitt Cancer Center Associate Professor, Radiology and Oncological Sciences, University of South Florida
Dr. El-Haddad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
12902 Magnolia Dr
Tampa, FL 33612Phone+1 813-745-1598- Is this information wrong?
Summary
- Dr. Ghassan El-Haddad is a radiologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Lebanese University School of Medicine and has been in practice 16 years. He specializes in nuclear medicine and vascular & interventional radiology.
Education & Training
University of Pennsylvania Health SystemFellowship, Interventional Radiology - Independent, 2011 - 2012
Quinnipiac University Frank H. Netter MD School of Medicine/St VIncent's Medical CenterResidency, Radiology-Diagnostic, 2008 - 2012- University of Pennsylvania Health SystemResidency, Nuclear Medicine, 2003 - 2006
SUNY Upstate Medical UniversityInternship, Internal Medicine, 2002 - 2003
Lebanese University School of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2012 - 2026
PA State Medical License 2003 - 2012
LA State Medical License 2006 - 2012
MI State Medical License 2005 - 2009- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Interventional Radiology and Diagnostic Radiology
Clinical Trials
- Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Start of enrollment: 2016 Mar 04
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver Start of enrollment: 2016 Mar 01
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2018 May 29
Publications & Presentations
PubMed
- Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.Jonathan R Strosberg, Taymeyah Al-Toubah, Ghassan El-Haddad, Diane Reidy Lagunes, Lisa Bodei> ;Journal of Nuclear Medicine. 2024 Mar 1
- Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.Tung-Hahn, E., El-Haddad, G., Strosberg, J.> ;Case Reports in Dermatological Medicine. 2024 Jan 1
- 3 citationsSomatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.Taymeyah Al-Toubah, Jaime Montilla-Soler, Ghassan El-Haddad, Mintallah Haider, Jonathan Strosberg> ;Journal of Nuclear Medicine. 2023 Dec 1
- Join now to see all
Journal Articles
- Melanocortin 1 Receptor Targeted Alpha-Particle Therapy for Metastatic Uveal Melanoma.Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalan..., J Nucl Med. 2019 Feb 7., 2/2019
Press Mentions
A Review of the VISION Trial: Lutetium-177-PSMA-617 Effective in Treating Metastatic Castration-Resistant Prostate CancerSeptember 10th, 2021
Professional Memberships
- Member
- Member
- Member
- Society of Nuclear Medicine and Molecular ImagingMember
- Cardiovascular and Interventional RadiologyMember
Hospital Affiliations
H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
